The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index, and 1 are not checked yet.
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Open accessAbstract
Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all “maybe” abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A meta-analysis reported 31%–73% of breast cancer survivors are adherent to AET,10”
From Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: Protocol for a pilot fractional factorial trial (2023) · cites this paper as [10]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of barriers to medication use have been reported in this setting, including medication side-effects, psychological distress and a lack of social support [4, 15].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Non -adherence to adjuvant endocrine therapy (AET) in women with breast cancer is common and associated with medication side -effects and distress.”
The cited source says what the claim attributes to it.
In the citing paper
“Adherence to adjuvant endocrine therapy is affected by medication side-effects and associated distress.”
The cited source says what the claim attributes to it.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
The cited source says what the claim attributes to it.
In the citing paper
“Non-adherence to AET is a major problem among women with breast cancer [4]”
In the citing paper
“Despite these benefits, between 31-73% of survivors discontinue adjuvant hormonal therapy in clinical practice,6 thereby reducing treatment efficacy.7-10”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, few interventions have been developed to improve adjuvant hormonal therapy adherence.6”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Patient variables (e.g., age), social support, patient-provider communication, and healthcare factors (e.g., cost) have been associated with breast cancer survivor adherence to systemic therapies.6, 16-18”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, adherence to hormonal therapy is suboptimal.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“While hormonal treatment related side effects such as hot flashes and osteoporosis42 represent one of the main reasons for discontinuation,6 none of the retrieved interventions had an explicit focus on side effects.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Although studies have shown that adherence is problematic in both older and younger women similarly,6 the reasons for discontinuation or barriers to adherence may be different between the two groups.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
From Cancer Patient to Cancer Survivor: Lost in Transition
(2005) · PsycEXTRA Dataset · doi:10.1037/e720092007-001 · Cited by 2,364
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Research works printed but not linked: 1
- Salgado BA, Zivian MT (2006) Aromatase inhibitors: side effects reported by 622 women. Breast Cancer Res Treat 100:S1618
Cited by
Sorted by citations
Items 101–200 of 710
Information exchange in oncological inpatient care – Patient satisfaction, participation, and safety
Kullberg, A., Sharp, L., Johansson, H., & Bergenmar, M. (2014) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2014.10.005 · Cited by 49
Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?
Kemp, A., Preen, D. B., Saunders, C. M., Boyle, F. M., Bulsara, M. K., Malacova, E., & Roughead, E. E. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-282 · Cited by 47
Symptom Clusters in Women With Breast Cancer During the First 18 Months of Adjuvant Therapy
Li, H., Sereika, S. M., Marsland, A. L., Conley, Y. P., & Bender, C. M. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.10.002 · Cited by 47
Braybrooke, J. P., Bradley, R., Hills, R. K., Peto, R., Kerr, A. J., Pan, H., Clarke, M. J., Dodwell, D. J., McGale, P., Taylor, C., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01013-x · Cited by 47
Meattini, I., Saieva, C., Marrazzo, L., Brina, L. D., Pallotta, S., Mangoni, M., Meacci, F., Bendinelli, B., Francolini, G., Desideri, I., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3565-2 · Cited by 46
Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer
Wassermann, J., Gelber, S. I., Rosenberg, S. M., Ruddy, K. J., Tamimi, R. M., Schapira, L., Borges, V. F., Come, S. E., Meyer, M. E., & Partridge, A. H. (2019) · Cancer · doi:10.1002/cncr.32192 · Cited by 46
AlOmeir, O., Patel, N., & Donyai, P. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05585-9 · Cited by 48
Priorities for Oncology Nursing Research: The 2013 National Survey
LoBiondo‐Wood, G., Brown, C. G., Knobf, M. T., Lyon, D., Mallory, G., Mitchell, S. A., Ah, D. M. V., Wesmiller, S. W., & Fellman, B. M. (2013) · Oncology nursing forum · doi:10.1188/14.onf.67-76 · Cited by 45
Acceptance and adherence to chemoprevention among women at increased risk of breast cancer
Roetzheim, R. G., Lee, J., Fulp, W. J., Gomez, E. M., Clayton, E., Tollin, S., Khakpour, N., Laronga, C., Lee, M. C., & Kiluk, J. V. (2014) · The Breast · doi:10.1016/j.breast.2014.11.006 · Cited by 44
Valente, S. A., Tendulkar, R. D., Cherian, S., Shah, C., Ross, D. L., Lottich, S. C., Laronga, C., Broman, K. K., Donnelly, E. D., Bethke, K. P., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09432-3 · Cited by 44
Kapoor, N. S., Shamonki, J. M., Sim, M., Chung, C. T., & Giuliano, A. E. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2924-7 · Cited by 43
Sentiment Analysis of an Online Breast Cancer Support Group: Communicating about Tamoxifen
Cabling, M. L., Turner, J. W., Hurtado‐de‐Mendoza, A., Zhang, Y., Jiang, X., Drago, F., & Sheppard, V. B. (2017) · Health Communication · doi:10.1080/10410236.2017.1339370 · Cited by 46
Moon, Z., Moss-Morris, R. E., Hunter, M. S., & Hughes, L. D. (2017) · British Journal of Health Psychology · doi:10.1111/bjhp.12274 · Cited by 44
Factors Associated with Endocrine Therapy Non‐Adherence in Breast Cancer Survivors
Spencer, J. C., Reeve, B. B., Troester, M. A., & Wheeler, S. B. (2020) · Psycho-Oncology · doi:10.1002/pon.5289 · Cited by 46
Calip, G. S., Boudreau, D. M., & Loggers, E. T. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2424-2 · Cited by 42
Qian, X.-L., Zhang, J., Li, P.-Z., Lang, R. G., Li, W., Sun, H., Liu, F.-F., Guo, X.-J., Gu, F., & Fu, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171169 · Cited by 42
The role of the pharmacist in improving medication beliefs and adherence in cancer patients
Birand, N., Boşnak, A. S., Diker, Ö., Abdi, A. M., & Başgut, B. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219831377 · Cited by 42
Lambert-Côté, L., Bouhnik, A., Bendiane, M., Bérenger, C., Mondor, M., Huiart, L., & Lauzier, S. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05549-x · Cited by 46
Mora, M. C. S., Pan, Y., Heisig, S. R., von Blanckenburg, P., Rief, W., Witzel, I., Albert, U., & Nestoriuc, Y. (2020) · Clinical Psychology in Europe · doi:10.32872/cpe.v2i1.2695 · Cited by 45
Jacobs, J. M., Post, K. E., Massad, K., Horick, N., Walsh, E. A., Cohn, J. G., Rapoport, C. S., Clara, A. J., Antoni, M. H., Safren, S. A., et al. (2022) · Cancer · doi:10.1002/cncr.34409 · Cited by 44
Wang, K., Ren, Y. T., Li, H., Zheng, K., Jiang, J., Zou, T., Ma, B., Li, H., Liu, Q., Ou, J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152312 · Cited by 41
Kroenke, C. H., Hershman, D. L., Gomez, S. L., Adams, S. R., Eldridge, E. H., Kwan, M. L., Ergas, I. J., Kubo, A., & Kushi, L. H. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4774-2 · Cited by 44
Farias, A. J., Hansen, R. N., Zeliadt, S. B., Ornelas, I. J., Li, C. I., & Thompson, B. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000351 · Cited by 41
Ahern, T. P., Hertz, D. L., Damkier, P., Ejlertsen, B., Hamilton-Dutoit, S. J., Rae, J. M., Regan, M. M., Thompson, A. M., Lash, T. L., & Cronin-Fenton, D. P. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kww178 · Cited by 42
Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer
Walker, H. E., Rosenberg, S. M., Stanton, A. L., Petrie, K. J., & Partridge, A. H. (2015) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2015.0051 · Cited by 39
Cavazza, M., Banks, H., Ercolanoni, M., Cukaj, G., Bianchi, G., Capri, G., & Longo, F. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05748-6 · Cited by 38
Valachis, A., Garmo, H., Weinman, J. A., Fredriksson, I., Ahlgren, J., Sund, M., & Holmberg, L. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3928-3 · Cited by 37
Cardoso, E., Csajka, C., Schneider, M. P., & Widmer, N. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0571-z · Cited by 37
Matikas, A., Foukakis, T., Swain, S. M., & Bergh, J. C. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz126 · Cited by 37
Age-related disparities in older women with breast cancer
Bagegni, N. A., & Peterson, L. L. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.01.003 · Cited by 37
Jacobs, J. M., Walsh, E. A., Park, E. R., Berger, J., Peppercorn, J. M., Partridge, A. H., Horick, N., Safren, S. A., Temel, J. S., & Greer, J. A. (2020) · International Journal of Behavioral Medicine · doi:10.1007/s12529-020-09908-2 · Cited by 37
Tan, E. H., Wong, A. L. A., Tan, C. C., Wong, P., Tan, S. H., Ang, L. E. Y., Lim, S. E., Chong, W. Q., Ho, J., Lee, S. C., et al. (2020) · The Breast · doi:10.1016/j.breast.2020.06.012 · Cited by 38
Remote Monitoring App for Endocrine Therapy Adherence Among Patients With Early-Stage Breast Cancer
Graetz, I., Hu, X. Y., Koçak, M., Krukowski, R. A., Anderson, J. N., Waters, T. M., Curry, A. N., Robles, A., Paladino, A. J., Stepanski, E. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.17873 · Cited by 39
Martínez-Pérez, C., Turnbull, A., Ekatah, G. E., Arthur, L. M., Sims, A. H., Thomas, J. S. J., & Dixon, J. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.009 · Cited by 36
Ethnic disparities in adherence to breast cancer survivorship surveillance care
Advani, P. S., Ying, B., Theriault, R. L., Melhem‐Bertrandt, A., Moulder, S. L., Bedrosian, I., Tereffe, W., Black, S., Pini, T. M., & Brewster, A. M. (2013) · Cancer · doi:10.1002/cncr.28490 · Cited by 39
Yin, Z., Harrell, M., Warner, J. L., Chen, Q., Fabbri, D., & Malin, B. (2018) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocy118 · Cited by 37
Daly, B., Olopade, O. I., Hou, N., Yao, K. A., Winchester, D. J., & Huo, D. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6380 · Cited by 36
Pan, Y., Heisig, S. R., von Blanckenburg, P., Albert, U., Hadji, P., Rief, W., & Nestoriuc, Y. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4637-2 · Cited by 35
Krok‐Schoen, J. L., Naughton, M. J., Young, G. S., Moon, J., Poi, M. J., Melin, S. A., Wood, M. E., Hopkins, J. O., Paskett, E. D., & Post, D. M. (2019) · Cancer Control · doi:10.1177/1073274819883287 · Cited by 38
Psychosocial determinants of adherence with oral anticancer treatment: ‘we don’t need no education’
Kaptein, A. A., Schoones, J. W., van der Meer, P. B., Matsuda, A., Murray, M., Heimans, L., & Kroep, J. R. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1843190 · Cited by 35
The role of CDK4/6 inhibitors in early breast cancer
Gil‐Gil, M., Alba, E., Gavilá, J., de la Haba-Rodríguez, J., Ciruelos, E. M., Tolosa, P., Candini, D., & Llombart‐Cussac, A. (2021) · The Breast · doi:10.1016/j.breast.2021.05.008 · Cited by 36
Arch, J. J., Crespi, C. M., Levin, M. E., Genung, S. R., Nealis, M., Mitchell, J. L., Bright, E. E., Albright, K., Magidson, J. F., & Stanton, A. L. (2022) · Annals of Behavioral Medicine · doi:10.1093/abm/kaab118 · Cited by 34
Valente, S. A., & Roesch, E. E. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27627 · Cited by 34
Londen, G. J. V., Donovan, H. S., Beckjord, E. B., Cardy, A., Bovbjerg, D. H., Davidson, N. E., Morse, J. Q., Switzer, G. E., Leeuw, I. M. V., & Dew, M. A. (2014) · Oncology nursing forum · doi:10.1188/14.onf.660-668 · Cited by 35
Xu, H., Jin, F., Zhang, X., Wang, D., Yu, S., & Wang, A. (2020) · Cancer Medicine · doi:10.1002/cam4.3017 · Cited by 35
Tinari, N., Fanizza, C., Romero, M., Gambale, E., Moscetti, L. I., Vaccaro, A., Seminara, P., Longo, F., Gori, S., Vici, P., et al. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.10.005 · Cited by 37
Bright, E. E., & Stanton, A. L. (2017) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000272 · Cited by 42
Multigene assays in early breast cancer: Insights from recent phase 3 studies
Markopoulos, C. J., Hyams, D. M., Gómez, H., Harries, M., Nakamura, S., Traina, T., & Katz, A. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.10.019 · Cited by 33
A Systematic Review of Repeat Fecal Occult Blood Tests for Colorectal Cancer Screening
Murphy, C. C., Sen, A., Watson, B., Gupta, S. N., Mayo, H., & Singal, A. G. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0775 · Cited by 33
Self-citationLailler, G., Memoli, V., Bihan-Benjamin, C. L., Diane, M.-K. B., Lauzier, S., Mancini, J., Bousquet, P., & Bouhnik, A. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.01.007 · Cited by 36
Advani, P. G., Advani, S., Nayak, P., VonVille, H. M., Diamond, P. M., Burnett, J., Brewster, A. M., & Vernon, S. W. (2021) · Journal of Cancer Survivorship · doi:10.1007/s11764-021-01046-2 · Cited by 35
Self-citationKarmakar, M., Pinto, S., Jordan, T. R., Mohamed, I., & Holiday-Goodman, M. (2017) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223417694520 · Cited by 34
Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients
Bell, S., Dalton, L. M., McNeish, B. L., Fang, F., Henry, N. L., Kidwell, K., & McLean, K. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.08.015 · Cited by 32
Blanchette, P., Lam, M., Richard, L., Allen, B. N., Shariff, S. Z., Vandenberg, T. A., Pritchard, K. I., Chan, K., Louie, A. V., Desautels, D. N., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05430-6 · Cited by 33
Franco, P., Rose, F. D., Santis, M. C. D., Pasinetti, N., Lancellotta, V., Meduri, B., & Meattini, I. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.02.003 · Cited by 35
Braal, C. L., Jager, A., Hoop, E. O., Westenberg, J. D., Lommen, K. M. W. T., de Bruijn, P., Vastbinder, M. B., van Rossum‐Schornagel, Q. C., Thijs-Visser, M. F., Alphen, R. J. V., et al. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01077-z · Cited by 32
Urban–Rural Variations in Quality-of-Life in Breast Cancer Survivors Prescribed Endocrine Therapy
Cahir, C., Thomas, A. A., Dombrowski, S. U., Bennett, K., & Sharp, L. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14040394 · Cited by 33
Yeh, C. H., Lin, W.-C., Suen, L. K. P., Park, N.-J., Wood, L. J., Londen, G. J. V., & Bovbjerg, D. H. (2017) · Oncology nursing forum · doi:10.1188/17.onf.476-487 · Cited by 32
Oncology providers’ perspectives on endocrine therapy prescribing and management
Wheeler, S., Roberts, M., Bloom, D., Reeder-Hayes, K., Espada, M., Peppercorn, J., Golin, C., & Earp, J. A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s95594 · Cited by 31
Balazard, F., Bertaut, A., Bordet, É., Mulard, S., Blanc, J., Briot, N., Paux, G., Mérimèche, A. D., Rigal, O., Coutant, C., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad109 · Cited by 32
Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer
Choong, G. M. Y., Hoskin, T. L., Boughey, J. C., Ingle, J. N., & Goetz, M. P. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02263 · Cited by 31
Toledo, G., Ochoa, C. Y., & Farias, A. J. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04814-0 · Cited by 31
Green, S. M. C., French, D., Graham, C. D., Hall, L., Rousseau, N. S., Foy, R., Clark, J., Parbutt, C., Raine, E., Gardner, B., et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08243-4 · Cited by 32
Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
Martínez-Cannon, B. A., Castro‐Sánchez, A., Barragán-Carrillo, R., Pacheco, S. D. L. R., Platas, A., Fonseca, A., Vega, Y., Bojoquez-Velazquez, K., Bargalló‐Rocha, E., Mohar, A., et al. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s296747 · Cited by 30
Smith, K. L., Verma, N., Blackford, A. L., Lehman, J., Westbrook, K. E., Lim, D., Fetting, J. H., Wolff, A. C., Jelovac, D., Miller, R. S., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00414-0 · Cited by 31
Markovitz, L. C., Drysdale, N. J., & Bettencourt, B. A. (2016) · Psycho-Oncology · doi:10.1002/pon.4362 · Cited by 32
Ali, E. E., Cheung, K. L., Lee, C. P., Leow, J. L., Yap, K. Y., & Chew, L. S. T. (2017) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/2347-5625.212864 · Cited by 32
Ryu, J. M., Yu, J., Kim, S. I., Kim, K. S., Moon, H., Choi, J. E., Jeong, J., Byun, K. D., Nam, S. J., Lee, S. K., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4472-5 · Cited by 30
Sitlinger, A. P., Shelby, R. A., Denburg, A. N. V., White, H. K., Edmond, S. N., Marcom, P. K., Bosworth, H. B., Keefe, F. J., & Kimmick, G. G. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.11.008 · Cited by 30
Spring, B. J., Stump, T. K., Penedo, F. J., Pfammatter, A. F., & Robinson, J. K. (2019) · Health Psychology · doi:10.1037/hea0000760 · Cited by 32
Sadigh, G., Gray, R. J., Sparano, J. A., Yanez, B. R., Garcia, S. F., Timsina, L., Sledge, G. W., Cella, D. F., Wagner, L. I., & Carlos, R. C. (2021) · Cancer · doi:10.1002/cncr.33527 · Cited by 30
Huiart, L., Bouhnik, A., Rey, D., Rousseau, F., Rétornaz, F., Meresse, M., Bendiane, M., Viens, P., & Giorgi, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081677 · Cited by 33
Mapping the Decision-Making Process for Adjuvant Endocrine Therapy for Breast Cancer
Beryl, L. L., Rendle, K. A. S., Halley, M. C., Gillespie, K. A., May, S. G., Glover, J., Yu, P. P., Chattopadhyay, R., & Frosch, D. L. (2016) · Medical Decision Making · doi:10.1177/0272989x16640488 · Cited by 29
Francis, K. E., Kim, S. I., Friedlander, M. L., Gebski, V., Ray-Coquard, I., Clamp, A. R., Penson, R. T., Oza, A. M., Perri, T., Huzarski, T., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.222 · Cited by 29
Dry eyes and AIs: If you don't ask you won't find out
Inglis, H., Boyle, F. M., Friedlander, M. L., & Watson, S. L. (2015) · The Breast · doi:10.1016/j.breast.2015.08.008 · Cited by 29
Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer
Kuba, S., Ishida, M., Nakamura, Y., Taguchi, K., & Ohno, S. (2014) · Breast Cancer · doi:10.1007/s12282-014-0540-4 · Cited by 30
Bhatta, S. S., Hou, N., Moton, Z., Polite, B. N., Fleming, G. F., Olopade, O. I., Huo, D., & Hong, S. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-356 · Cited by 30
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
Buijs, S. M., Koolen, S. L. W., Mathijssen, R. H. J., & Jager, A. (2024) · Drugs · doi:10.1007/s40265-024-02010-x · Cited by 28
Fatores associados à adesão e à persistência na hormonioterapia em mulheres com câncer de mama
Guedes, J. B. R., Guerra, M. R., Alvim, M. M., & Leite, I. C. G. (2017) · Revista Brasileira de Epidemiologia · doi:10.1590/1980-5497201700040007 · Cited by 28
Goldberg, M., Sutradhar, R., Paszat, L. F., Whelan, T. J., Gu, S., Fong, C. H., & Rakovitch, E. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05266-0 · Cited by 28
Hack, C., Voiß, P., Lange, S., Paul, A., Conrad, S., Dobos, G., Beckmann, M. W., & Kümmel, S. (2015) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0035-1557748 · Cited by 28
Lindblad, C., Langius‐Eklöf, A., Petersson, L., Sackey, H., Bottai, M., & Sandelin, K. (2018) · Psycho-Oncology · doi:10.1002/pon.4702 · Cited by 28
Aromatase inhibitors: the journey from the state of the art to clinical open questions
Generali, D., Berardi, R., Caruso, M., Cazzaniga, M. E., Garrone, O., Minchella, I., Paris, I., Pinto, C., & Placido, S. D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1249160 · Cited by 27
ACSL4-mediated H3K9 and H3K27 hyperacetylation upregulates SNAIL to drive TNBC metastasis
Sinha, A., Saini, K. K., Chandramouli, A., Tripathi, K., Khan, M. A., Satrusal, S. R., Verma, A., Mandal, B., Rai, P., Meena, S., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2408049121 · Cited by 28
Sleep and endocrine therapy in breast cancer
Dyk, K. V., Joffe, H., & Carroll, J. (2021) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2021.03.007 · Cited by 27
Yang, Y., Wei, W., Jin, L., He, H., Wei, M., Shen, S., Pi, H., Liu, Z., Li, H., & Liu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.783487 · Cited by 27
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer
Pagliuca, M., Donato, M., D’Amato, A. L., Rosanova, M., Russo, A. O. M., Scafetta, R., Angelis, C. D., Trivedi, M. V., André, F., Arpino, G., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103861 · Cited by 27
Persistence to 5-year hormonal breast cancer therapy: a French national population-based study
Bosco‐Lévy, P., Jové, J., Robinson, P., Moore, N. D., Fourrier‐Réglat, A., & Bezin, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.276 · Cited by 30
Humphries, B., Collins, S., Guillaumie, L., Lemieux, J., Dionne, A. R., Provencher, L., Moisan, J., & Lauzier, S. (2018) · Pharmacy · doi:10.3390/pharmacy6020053 · Cited by 31
Paladino, A. J., Anderson, J. N., Krukowski, R. A., Waters, T. M., Koçak, M., Graff, J. C., Blue, R., Jones, T. N., Buzaglo, J. S., Vidal, G. A., et al. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4588-x · Cited by 28
Jiang, H., Dong, Y. J., Zong, W., Zhang, X., Xu, H., & Jin, F. (2022) · BMC Women s Health · doi:10.1186/s12905-022-01722-0 · Cited by 29
Analysis of breast cancer in young women in the Department of Defense (DOD) database
Zimmer, A. S., Zhu, K., Steeg, P. S., Wu, A. M. L., Gatti-Mays, M. E., Soltani, S., Perkins, J. G., Shao, S., Brown, D. W., Georg, M. W., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4615-8 · Cited by 26
Lee, H. S., Lee, J., Ah, Y.-M., Kim, H. S., Im, S., Noh, D., & Lee, B. K. (2014) · Oncology · doi:10.1159/000360702 · Cited by 26
Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer
Robinson, B. A., Dijkstra, B., Davey, V., Tomlinson, S., & Frampton, C. M. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.10.015 · Cited by 25
Yu, J., Wu, J., Huang, O., Chen, X., & Shen, K. (2021) · Journal of Medical Internet Research · doi:10.2196/27576 · Cited by 28
Cloud, A. J., Thai, A., Liao, Y., & Terry, M. B. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3234-x · Cited by 25
Dorfman, C. S., Arthur, S. S., Kimmick, G. G., Westbrook, K. E., Marcom, P. K., Corbett, C. M., Edmond, S. N., & Shelby, R. A. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001337 · Cited by 25
Dumas, É., Jochum, F., Coussy, F., Hamy, A., Majdling, A., Houzard, S., Bihan-Benjamin, C. L., Reyal, F., Gougis, P., & Stensrud, M. J. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.24.01131 · Cited by 24
Pritchard, K. I., Gelmon, K. A., Rayson, D., Provencher, L., Webster, M., McLeod, D., & Verma, S. (2013) · Current Oncology · doi:10.3747/co.20.1316 · Cited by 24
Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy
Yanez, B. R., Gray, R. J., Sparano, J. A., Carlos, R. C., Sadigh, G., Garcia, S. F., Gareen, I. F., Whelan, T. J., Sledge, G. W., Cella, D. F., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.1693 · Cited by 24
Metadata
- Authors
- Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Murphy, Caitlin C.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2012-06-12
- Volume
- 134
- Issue
- 2
- Pages
- 459-478
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC3607286
- OpenAlex
- W1987753117
- Semantic Scholar
- 92816b1cff05e88d3955bfa52d7d9c9f3eafb040
- Cited by
- 708
- References
- 85
- Citations by year
- 2026: 32 · 2025: 63 · 2024: 59 · 2023: 67 · 2022: 71 · 2021: 59 · 2020: 60 · 2019: 54 · 2018: 41 · 2017: 64 · 2016: 33 · 2015: 38 · 2014: 32 · 2013: 34 · 2012: 1
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R25CA057712, R01CA112223, K07CA140159)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- adjuvant endocrine therapy, breast cancer survivors, medication adherence, treatment persistence, tamoxifen, aromatase inhibitors, hormone receptor-positive breast cancer, out-of-pocket costs, treatment side effects, behavioral interventions
- MeSH terms
- Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Neoplasms, Hormone-Dependent, Chemotherapy, Adjuvant, Survivors, Antineoplastic Agents, Hormonal, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
